|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02315 BIOCYTOGEN-B
Nominal 
56.050 -2.050 (-3.528%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Turnover | 941,389 | 51.601% | 620,963 | 410,499 | 326,836 | 229,131 |
| Cost of Sales | (194,899) | 22.567% | (159,014) | (105,006) | (91,472) | (62,161) |
| Gross Profit | 746,490 | 61.596% | 461,949 | 305,493 | 235,364 | 166,970 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 41,572 | 99.904% | 20,796 | 6,483 | 942 | 10,233 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (20,501) | 72.917% | (11,856) | (9,085) | (4,983) | (9,484) | |
| Profit / (Loss) before Taxation | 248,569 | 316.922% | 59,620 | (47,077) | (189,389) | (272,593) | |
| Taxation | (7,475) | -35.677% | (11,621) | (3,596) | (420) | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 1 | -- | 0 | 0 | 1 | 208 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 241,095 | 402.292% | 47,999 | (50,673) | (189,808) | (272,385) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 33,415 | -0.450% | 33,566 | 49,280 | 41,160 | 18,187 |
| Depreciation & Amortisation | 81,660 | -4.041% | 85,099 | 85,461 | 84,063 | 77,402 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| EPS (cts) | 54.000 | 350.000% | 12.000 | -13.000 | -48.000 | -73.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 5.419 | -- | 2.233 | 1.852 | 2.405 | -- |
| Remarks: | Real time quote last updated: 11/09/2026 09:49 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 241,095 |
| %Change | 402.292% |
| EPS / (LPS) | RMB 0.540 |
| NBV Per Share (¥) | RMB 5.419 |